| 000 | 00000nam 2200000zi 4500 |
| 001 | 9.950905 |
| 003 | CaOODSP |
| 005 | 20250521125201 |
| 006 | m o d f |
| 007 | cr mn||||||||| |
| 008 | 250507e202505 onc ob f000 0 eng d |
| 020 | |a9780660772011 |q(statement) |
| 020 | |a9780660772028 |q(summary) |
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
| 043 | |an-cn--- |
| 086 | 1 |aHP40-389/2025E-PDF |
| 086 | 1 |aHP40-389/2025-1E-PDF |
| 245 | 00|aNACI rapid response : |bupdated guidance on the use of Imvamune® for the prevention of mpox. |
| 264 | 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cMay 2025. |
| 264 | 4|c©2025 |
| 300 | |a1 online resource (27 pages) + |esummary (5 pages) |
| 336 | |atext|btxt|2rdacontent |
| 337 | |acomputer|bc|2rdamedia |
| 338 | |aonline resource|bcr|2rdacarrier |
| 500 | |aIssued also in French under title: Réponse rapide du CCNI : mise à jour des directives sur l'utilisation d'ImvamuneMD pour la prévention de la mpox. |
| 500 | |aFrom the cover: An Advisory COmmittee Statement (ACS). National Advisory Committee on Immunization (NACI)." |
| 500 | |a"Pub.: 250051." |
| 500 | |a"Pub.: 250053." |
| 504 | |aIncludes bibliographical references (pages 23-27). |
| 650 | 0|aHuman monkeypox|xVaccination|zCanada. |
| 650 | 0|aHuman monkeypox|xVaccination|xGovernment policy|zCanada. |
| 710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
| 710 | 1 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body. |
| 775 | 08|tRéponse rapide du CCNI : |w(CaOODSP)9.950906 |
| 856 | 40|qPDF|s482 KB|uhttps://publications.gc.ca/collections/collection_2025/aspc-phac/HP40-389-2025-eng.pdf|z(statement) |
| 856 | 40|qPDF|s253 KB|uhttps://publications.gc.ca/collections/collection_2025/aspc-phac/HP40-389-2025-1-eng.pdf|z(summary) |
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-rapid-response-updated-guidance-use-imvamune-prevention-mpox.html|z(summary) |